OnKure Therapeutics, Inc. financial data

Symbol
OKUR on Nasdaq
Location
6707 Winchester Circle, Suite 400, Boulder, CO
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.11K % -40.3%
Debt-to-equity 10.2 %
Return On Equity -74.9 % -628%
Return On Assets -67.9 % -181%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 33.4M shares -1.1%
Common Stock, Shares, Outstanding 3.34M shares -90.1%
Entity Public Float 27.7M USD -81.7%
Common Stock, Value, Issued 0 USD -100%
Weighted Average Number of Shares Outstanding, Basic 13.5M shares +4180%
Weighted Average Number of Shares Outstanding, Diluted 13.5M shares +4180%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 51.9M USD +130%
General and Administrative Expense 15.6M USD +157%
Operating Income (Loss) -67.5M USD -363%
Net Income (Loss) Attributable to Parent -63.5M USD -280%
Earnings Per Share, Basic 93 USD/shares +97%
Earnings Per Share, Diluted 93 USD/shares +97%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 70.3M USD +15.9%
Cash, Cash Equivalents, and Short-term Investments 76.7M USD
Assets, Current 71.5M USD -7.11%
Property, Plant and Equipment, Net 720K USD +1120%
Operating Lease, Right-of-Use Asset 485K USD +10.2%
Other Assets, Noncurrent 104K USD -29.3%
Assets 72.8M USD -6.2%
Accounts Payable, Current 1.29M USD +444%
Employee-related Liabilities, Current 2.98M USD
Accrued Liabilities, Current 4.66M USD +389%
Liabilities, Current 6.25M USD +92.3%
Operating Lease, Liability, Noncurrent 120K USD -68.3%
Other Liabilities, Noncurrent 40K USD
Liabilities 6.41M USD +76.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 2K USD
Retained Earnings (Accumulated Deficit) -201M USD +14.9%
Stockholders' Equity Attributable to Parent 66.4M USD
Liabilities and Equity 72.8M USD -6.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -14M USD -31.8%
Net Cash Provided by (Used in) Financing Activities -77K USD -870%
Net Cash Provided by (Used in) Investing Activities -18K USD
Common Stock, Shares Authorized 210M shares +5%
Common Stock, Shares, Issued 3.34M shares -90.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -14.1M USD -32.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 70.3M USD +784%
Deferred Tax Assets, Valuation Allowance 90.9M USD +309%
Deferred Tax Assets, Gross 90.9M USD +309%
Operating Lease, Liability 687K USD +3.31%
Payments to Acquire Property, Plant, and Equipment 18K USD +100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -41M USD +39.2%
Lessee, Operating Lease, Liability, to be Paid 705K USD -6.5%
Property, Plant and Equipment, Gross 2.08M USD
Operating Lease, Liability, Current 567K USD +98.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 560K USD +52.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 560K USD +50.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 18K USD -79.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 285K USD -25.2%
Deferred Tax Assets, Operating Loss Carryforwards 54M USD +498%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 34K USD -88.1%
Operating Lease, Payments 140K USD +164%
Additional Paid in Capital 267M USD -13.8%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 459K USD -5.26%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 11.1M USD +3745%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares